Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016 (2016), Article ID 7625940, 5 pages
http://dx.doi.org/10.1155/2016/7625940
Case Report

Poor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases

1Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA
2Department of Pathology, Stony Brook University Hospital, Stony Brook, NY, USA
3Division of Hematology and Oncology, Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA
4Division of Gastroenterology, Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA

Received 4 June 2016; Accepted 8 September 2016

Academic Editor: Peter F. Lenehan

Copyright © 2016 Brandon Yim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatic amyloidosis is a rare disease entity that results from insoluble amyloid protein deposition in the liver. The disease often presents with vague, nonspecific clinical features. Currently, there is little literature describing treatment outcomes for biopsy-proven hepatic amyloidosis and current treatment guidelines recommend that patients enroll in a clinical trial due to insufficient evidence to suggest an optimal treatment regimen. Here, we present two cases of hepatic amyloidosis at an academic medical center and describe their presentation, treatment, and outcomes. These cases highlight the poor outcomes and difficult management of hepatic amyloidosis. Further understanding and investigation of this rare disease are warranted.